Seltorexant for Depression

"Janssen Research & Development, LLC's Seltorexant is presently being trialled across 28 countries and 133 cities. This drug received its initial approval in 2020 as part of a Phase 1 trial which included 64 participants. Since then, 18341 studies have been concluded regarding this medication."

"To be eligible for this trial, subjects must fall between the age of 12 and 17. Across the nation, there are 192 clinical trials open to minors, while 968 studies exist that focus on seniors over 65 years old."

"In 2020, Seltorexant was initially trialed at Universitaetsklinikum der RWTH Aachen. To-date, 18341 studies have been concluded with 6 active trials taking place in The Woodlands, Texas."

"According to the information provided on clinicaltrials.gov, this medical trial is currently looking for patients. It was first posted in September 2021 and recently updated in November 2022."

"Janssen Research & Development, LLC., the sponsor of this clinical trial, has specified that it will be measuring and reporting on Treatment Emergent Adverse Events (TEAEs) over a period of up to 6 weeks as its primary outcome. Secondary outcomes include Change in Subjective Sleep Related Impairment (PROMIS-Pediatric-Sleep-Related Impairment [SRI]), measured using an 8 question Likert scale with higher scores indicating more sleep disturbance; Change from Baseline to Week 6/End of Treatment (EOT) in the Children's Depression Rating Scale (CDRS) Total Score; and change"

"As Seltorexant is only in its first phase of clinical trials, the safety rating assigned by our team was 1 due to the limited evidence collected thus far."

"Affirmative. According to clinicaltrials.gov, this study is actively enrolling participants; it was initially uploaded on September 2nd 2021 and underwent its last update November 9th 2022. The trial requires 52 recruits from 12 different medical centres."

"This clinical trial is seeking 52 adolescents aged 12 to 17 who are suffering from involutional psychosis. To be eligible, participants must possess a Children's Depression Rating Scale-Revised (CDRS-R) score of at least 48 with no more than 25% improvement during screening; have responded inadequately (<50%) to one or two antidepressant treatments including fluoxetine and escitalopram after 6 weeks on the minimum therapeutic dose, 4 weeks on the optimal dose prior to screening; weigh between the fifth and ninety-fifth percentile for age and sex (with obese patients above 95th percentile OR underweight ones below 5th percentile"

"This trial is presently enrolling participants from a dozen sites, which are situated in The Woodlands, Dallas and South Bend amongst other cities. To minimize commuting to the medical centre for check-ups, it would be best if you select a site close by when signing up."